Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

3(50.0%)

Phase 1

2(33.3%)

Phase 4

1(16.7%)

6Total

Phase 2(3)

Phase 1(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05394740Phase 1Completed

Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy

Role: collaborator

NCT05694819Phase 2Completed

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Role: collaborator

NCT04724460Phase 4Completed

Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer

Role: collaborator

NCT03406871Phase 1Completed

Regorafenib and Nivolumab Simultaneous Combination Therapy

Role: collaborator

NCT03305224Phase 2Unknown

The Combination Therapy With Ra-223 and Enzalutamide

Role: collaborator

NCT04600492Phase 2Unknown

THERAPY-HYBRID-BPA Trial

Role: collaborator

All 6 trials loaded